Preclinical mechanistic study

Reverse Effects of Nicotinamide Mononucleotide Supplementation on Declining Quality of Oocytes With Polycystic Ovary Syndrome

Yong Fan et al. · The FASEB Journal · 2025

Evidence type: Preclinical mechanistic study Interpretive weight: Mechanistic contextResearch area: PCOS oocyte quality and reproductive metabolism
DesignPreclinical reproductive study using a dehydroepiandrosterone-induced PCOS mouse model, in-vitro oocyte maturation, transcriptomics, mitochondrial and spindle assays, and NMNAT/SIRT1 mechanistic experiments.
PopulationOocytes collected from female mice with experimentally induced PCOS; no human participants.
SampleMultiple oocyte experiments with group sizes varying by assay; key maturation analyses used about 60 oocytes per group and NAD+ assays about 80 oocytes per group, with three independent experiments.
InterventionExogenous NMN supplementation during in-vitro maturation of oocytes collected from PCOS-model mice, tested across concentrations to identify effects on maturation and oocyte quality.
EndpointsGerminal-vesicle breakdown and first-polar-body extrusion; Oocyte NAD+ levels; Transcriptomic changes; Reactive oxygen species and apoptosis; Mitochondrial distribution, membrane potential, and ATP; Spindle morphology; NMNAT/SIRT1 pathway dependence

What the publication reported

This preclinical study used a mouse model of polycystic ovary syndrome (PCOS) to test whether adding NMN during in-vitro maturation could improve oocyte quality.

PCOS-model oocytes had lower NAD+ and impaired maturation. NMN supplementation increased NAD+, improved germinal-vesicle breakdown and first-polar-body extrusion, reduced oxidative-stress and apoptosis signals, improved mitochondrial measures, and reduced spindle abnormalities.

Mechanistic experiments implicated the NAD+ salvage pathway, NMNAT enzymes, and SIRT1. These findings are from mouse oocytes matured in vitro and do not establish fertility or pregnancy benefits in women with PCOS.

Key findings

  • PCOS-model oocytes showed lower NAD+ and poorer in-vitro maturation than controls.
  • NMN supplementation improved germinal-vesicle breakdown and first-polar-body extrusion rates in the reported experiments.
  • NMN partially restored the transcriptomic profile of PCOS oocytes.
  • Oxidative-stress, mitochondrial dysfunction, spindle abnormality, and apoptotic signaling were reduced with NMN.
  • NMN improved mitochondrial membrane potential and ATP-related measures.
  • NMNAT/SIRT1 pathway experiments supported a mechanistic role for NAD+ salvage in the observed effects.

What it cannot establish

  • The study used a mouse PCOS model and isolated oocytes rather than women with PCOS.
  • NMN was added during in-vitro maturation rather than administered as a standard oral supplement.
  • Oocyte maturation and cellular-quality measures are surrogate reproductive endpoints, not pregnancy or live-birth outcomes.
  • The experiment does not establish an effective or safe human dose.
  • The model cannot address whole-body endocrine, metabolic, or long-term reproductive effects in people.
HealthspanX claim boundary: This study does not establish that NMN treats PCOS, improves fertility, pregnancy rates, embryo quality, or live-birth outcomes in humans.

Continue reviewing

Return to the complete evidence library.

Evidence Center Ultra Pure NMN

Source fields verified